Management of plastic bronchitis with nebulized tissue plasminogen activator: another brick in the wall by Massimo Colaneri et al.
ITALIAN JOURNAL
OF PEDIATRICS
Colaneri et al. Italian Journal of Pediatrics 2014, 40:18
http://www.ijponline.net/content/40/1/18CASE REPORT Open AccessManagement of plastic bronchitis with nebulized
tissue plasminogen activator: another brick in
the wall
Massimo Colaneri1, Andrea Quarti1, Marco Pozzi1, Stefano Gasparini2, Ines Carloni3
and Fernando Maria de Benedictis3*Abstract
Plastic bronchitis is a rare complication of a variety of respiratory diseases and congenital heart disease surgery,
particularly Fontan procedure. Bronchial casts with rubber-like consistency develop acutely and may cause severe
life-threatening respiratory distress. The management of plastic bronchitis is yet not well defined. Early intermittent,
self-administered nebulization of tissue plasminogen activator was found to be effective in preventing deterioration
of acute respiratory symptoms in a patient with primary ciliary dyskinesia and recurrent cast formation. Further
investigation into new therapeutic strategies for this devastating disease is advocated.
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Plastic bronchitis (PB) is an uncommon condition charac-
terized by mucoid impaction with casts that occlude major
bronchi and cause acute, potentially fatal bronchial ob-
struction [1]. PB has been associated with a variety of re-
spiratory diseases, but is found most commonly as a
secondary phenomenon after Fontan surgery in patients
with cyanotic congenital heart disease (CHD) [2]. Especially
in these patients, recurrences are common and mortality
remains high. Patients either expectorate casts spontan-
eously, coughing up a firm mucus material, or may require
urgent bronchoscopy to remove casts and avoid impending
respiratory arrest due to airway obstruction.
The pathophysiology of PB remains to be elucidated. It
has been suggested that high pulmonary venous pressures
may lead to an abnormal response of respiratory epithe-
lium and/or lymphatic dysfunction, thus resulting in
excess mucus production and cast formation. An under-
lying genetic predisposition associated with an inflamma-
tory trigger was also postulated to explain the abnormal
mucin hypersecretion [3]. PB has been classified in type 1
(inflammatory) and 2 (noninflammatory) according to the* Correspondence: debenedictis@ospedaliriuniti.marche.it
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stated.characteristics of casts. Because inflammation is thought
to play a role in the formation of all casts, Madsen et al.
[3] have recommended classification based on associated
disease first and on cast histology second.
We report the case of an adolescent with CHD and pri-
mary ciliary dyskinesia (PCD) who developed features of
PB and severe respiratory failure 7 yrs apart from Fontan
operation. The occurrence of PB in our patient let us
hypothesize that decreased mucociliary clearance was an
adjunctive trigger for the development of PB. The effect of
early, intermittent nebulization of recombinant human tis-
sue plasminogen activator (t-PA) therapy is described.Case presentation
A 13-year-old boy presented with a history of 10-day fever,
cough, and progressive dyspnea which persisted despite
antibiotic treatment. He was born with right atrial isomer-
ism, situs viscerum inversus, asplenia and complex CHD
characterized by double outlet right ventricle, great arter-
ies transposition, pulmonary artery stenosis, ventricular
septal defect and common atrio-ventricular valve. At age
2 yrs, PCD was diagnosed by electron microscope speci-
men examination of respiratory cilia (100 percent of ab-
normal cilia with both inner and outer dynein arm defect).
Glenn operation and fenestrated extracardiac Fontan sur-
gery were performed at age 3 yrs and 6 yrs, respectively.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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pulmonary disease. For recurrent wheezing and productive
cough with abundant, thick expectoration, regular antiasth-
matic treatment and chest physiotherapy was instituted.
At admission, physical examination revealed a child in
severe respiratory distress; scattered, harsh breath sounds
were present at chest auscultation. Blood pressure was 50/
40 mmHg. Arterial blood gas analysis showed pH 6.9,
PaO2 61 mmHg, SaO2 88%, PaCO2 150 mmHg. The pa-
tient was immediately intubated and mechanically venti-
lated, and was admitted to the Intensive Care Unit. Chest
radiography revealed patchy consolidation in the right
middle lobe and mild pleural effusion. Echocardiography
showed an ejection fraction of 55% and moderately dilated
inferior vena cava (IVC) and superior vena cava (SVC),
with normal flow and low blood velocity. A low cardiac
output syndrome occurred with multiorgan failure, requir-
ing a continuous veno-venous ultrafiltration and pharmaco-
logic support, including intravenous dopamine, epinephrine
and enoximone. Cardiac catheterization showed satisfactory
hemodynamics with no obstruction of the Fontan circula-
tion; IVC and SVC pressure was 21 mmHg; total pulmon-
ary resistance and arteriolar pulmonary resistance were 3,8
U/m2 and 1,5 U/m2, respectively. The QP/QS ratio was 0,9
and no stenosis at the anastomotic site was demonstrated.
A flexible fiber optic bronchoscopy revealed large, mucin-
ous casts partially obstructing the airway tree. Rigid bron-
choscopy was required to remove the casts (Figure 1). An
immediate and sustained improvement in oxygenation was
obtained. Histological examination revealed mostly mucous
material with fibrin and rare inflammatory cells. Cultures
taken from the casts were negative. The patient was extu-
bated on hospital day 12 and was maintained on therapyFigure 1 Large mucinous cast removed by rigid bronchoscopy.with albuterol, N-acetylcysteine, budesonide, deoxyribo-
nuclease (DNase) by nebulization, and oral sildenafil. Des-
pite such therapy, other two episodes of respiratory
deterioration occurred over the following 10 days, each re-
quiring bronchoscopic removal of casts from the bronchial
tree. After the latest episode, treatment with aerosolized t-
PA (Actilyse, Boehringer Ingelheim) was added to the previ-
ous therapy. A total of 5 ml of the drug diluted to 1 mg/ml
of normal saline was delivered every 6 hours via a Pari
TurboBoy S compressor with a Pari LC Sprint reusable
nebulizer and a mask (Pari GmbH, Starnberg, Germany).
Over the next few days, the child started expectorating
thinner bronchial secretions and his condition improved
gradually, with clearing of areas of atelectasis and no re-
currence of respiratory symptoms. The patient was dis-
charged home receiving budesonide (0,5 mg twice
daily), DNase (1,25 mg twice daily) and t-PA (5 mg four
times daily) by nebulization, oral sildenafil, and chest
physiotherapy.
During an elective admission after 2 months, an attempt
at gradually suspending t-PA treatment was successful. At
discharge, parents received instructions to reintroduce a
course of t-PA at the onset of symptoms or signs (cough,
expectoration or chest discomfort) that they identified as
their child’s usual starting point before the development of
PB. T-PA starting dose of 5 mg had to be repeated after 15
and 60 min, and then continued four times daily for 7 days
or until symptoms had completely resolved. Parents were
also instructed to refer immediately the child to the hospital
if symptoms had not improved after the first three doses,
and to regularly contact the medical staff within 24 hours
after starting treatment in order to report the event. During
12 month follow-up, this therapeutic regimen had to be
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gested an impending risk of cast formation. Prompt and
complete relief was obtained in each occasion, with no side
effects and no further hospital admissions.
Discussion
Patients with CHD who received Fontan operation have
more life-threatening events and a greatest mortality rate
due to episodes of PB compared with those with other
underlying diseases [4]. Preventing recurrence of PB is
therefore a major challenge for patients with Fontan physi-
ology. Optimization of cardiac output and consideration of
low-fat diet or thoracic duct ligation are important thera-
peutic measures. The indication for heart transplantation
remains uncertain, particularly in patients who improve on
full medical treatment.
Over the years, strategies to enhance cast expectoration
or to induce lysis of casts have been repeatedly claimed.
Several drugs for the treatment of PB have been used, in-
cluding antibiotics, steroids, bronchodilators, diuretics,
unfractionated heparin, N-acetylcysteine, urokinase, DNase
and t-PA [1]. However, most of the evidence on the effect
of pharmacologic therapy comes from individual case re-
ports or small case series that do not allow to compare the
efficacy of a drug against the others. Furthermore, most pa-
tients received a number of different medications making it
difficult to ascertain which of them is really effective.
We believe that our case is worth mentioning for several
reasons. First, a long delay in presenting symptoms of PB
after Fontan surgery is unusual [5], as the onset of PB
is typically within 1 to 3 years after surgical operation.
This finding alerts to regularly evaluate cardiac function
and watch over the symptoms of PB in patients who re-
ceived Fontan intervention. Second, only one case of PB
in Kartagener’s syndrome has been reported so far, and
the therapeutic approach after emergency removing of
bronchial casts was not described [6]. It is likely that
underlying immotile cilia dysfunction and decreased
mucociliary clearance may influence the development
of recurrent bronchial casts in patients with associated
PCD and CHD who received Fontan circulation. Third,
we first report on the efficacy of intermittent use of
aerosolized t-PA in preventing recurrence of PB. Given
the severity of symptoms before starting t-PA, the im-
provement observed in our patient was a likely conse-
quence of treatment and not a simple matter of time.
T-PA is a serine protease which exerts the fibrinolytic
action by catalyzing the conversion of plasminogen to
plasmin. Quasney et al. [7] first demonstrated that bron-
chial casts were unchanged with in vitro saline incubation,
became soft and friable when incubated with urokinase,
but dissolved completely when incubated in a t-PA solu-
tion. Gibb et al. [8] first demonstrated that direct instilla-
tion of t-PA into the airways during bronchoscopy was aneffective therapy for PB, being superior to nebulized
DNase. A recent retrospective study reported that casts in
patients with CHD and Fontan physiology are predomin-
antly hypocellular and fibrinous, thus substantiating the
role of local t-PA therapy [9].
There have been several reports on the effect of inhaled
t-PA in improving PB. However, the optimal dosing strategy
and the duration of therapy remain unclear. Repeated doses
up to 2 mg/kg per day have been used with success without
important side effects [4]. In a ex vivo study, increasing
amounts of aerosolized t-PA did not improve cast weight
reduction and no evidence of dose–response effect was
found using this endpoint [10]. Furthermore, 28-day re-
peated administration of high doses (>1 mg/kg/day) inhaled
t-PA in mice resulted in pulmonary haemorrhage, whereas
low-dose therapy was well tolerated [11]; it was supposed
that this side effect may be the consequence of the drug ac-
cumulation in the lungs. Since rigorous information on the
optimal t-PA dosage is lacking, low doses (0.5 mg/kg) have
been used in our experimental protocol. We cannot how-
ever exclude that higher doses may be more effective, espe-
cially if casts are refractory to treatment.
Should t-PA therapy be administered on continuous
basis to prevent cast formation? The actual experience is
largely anecdotal. In a patient who had failed several at-
tempts to stop treatment, long-term administration of
aerosolized t-PA was highly effective to avoid recurrent
episodes of life-threatening airway obstruction, and was
safe [12]. Regular nebulization of t-PA has been recently
included into a multi-drug protocol of medical treatment,
but the results are limited to less than 1 year follow-up
[4]. Interestingly, a new strategy on alternate weeks t-PA
administration led to no recurrence of cast formation in a
4-year old boy with Fontan circulation [13].
T-PA is extremely expensive. We speculated that early,
intermittent nebulization of this drug during a pre-defined
acute episode instead of regular, “preventive” administra-
tion may avoid the progression of respiratory symptoms
and reduce costs. This strategy was effective and safe in
our patient. As vain attempts to wean patients with recur-
rent PB off regular therapy with t-PA have been described
[12,13], it seems however prudent to taper the treatment
gradually under close medical supervision. Whether regu-
lar t-PA administration is more effective than intermittent
strategy needs to be ascertained in future studies.
In conclusion, prompt self-administration of t-PA avoided
the recurrence of cast formation in a child with PCD and
Fontan physiology. Given our single case experience, such
strategy should be limited to patients who were able to
interrupt regular treatment with t-PA with no deterioration.
Characterizing t-PA distribution in the airway in order to
optimize the dose delivered to the lungs, understanding
whether patients with particular casts histology (i.e. high fi-
brin concentration) may better benefit by t-PA inhalation
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some key points to be urgently identified. An International
Plastic Bronchitis registry to collect data on patients world-
wide (www.clinicaltrials.gov, NCT01663948) has been re-
cently established with the aim to answer still unresolved
questions for this devastating disease [14].
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